iib/iiia

Tirofiban hydrochloride monohydrate (MK-383 Hydrochloride) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist.

Lefradafiban（BIBU-104） is an oral platelet glycoprotein IIb/IIIa receptor antagonist for the study of angina pectoris and acute coronary syndromes.

Roxifiban acetate（DMP 754 acetate） is a potent GP IIb / IIIa antagonist that exhibits antiplatelet aggregation activity via immune mediation and can be used in the study of human thrombocytopenia.

Eptifibatide acetate (148031-34-9 free base) (Eptifibatide acetate) , an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class, is a cyclic heptapeptide constructed from 6 amino acids and a mercaptopropionyl residue.

Gantofiban is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist used in the treatment of cardiovascular disease and may be used to study thrombosis.

Orbofiban, an orally administered antagonist of the platelet GPIIb/IIIa receptor, effectively inhibits platelet aggregation.

Roxifiban, a prodrug of XV459, is an antiplatelet agent with high affinity and specificity for platelet glycoprotein IIb/IIIa complex(GPIIb/IIIa) receptors.

GPRP acetate (Pefabloc FG) is fibrinogen-related peptides, which inhibit the interaction of fibrinogen with the platelet membrane glycoprotein IIbIIIa complex (GPIIbIIIa).

SKF 106760 is used as a glycoprotein IIb/IIIa antagonist.

L-739758 is a glycoprotein IIb/IIIa inhibitor.

Collagen-IN-1 (compound 3) is an ortho-carbonyl hydroquinone derivative that selectively inhibits collagen. It non-competitively inhibits agonist-induced platelet aggregation, with an IC50 value of 1.77 μM. Collagen-IN-1 reduces P-selectin expression, glycoprotein IIb IIIa activation, and the release of adenosine triphosphate and CD63 from platelets. This compound is promising for research into platelet-related thrombosis diseases [1].

platelet fibrinogen receptor glycoprotein IIb/IIIa (GpIIb/IIIa) antagonist

Lotrafiban hydrochloride is an platelet glycoprotein IIb/IIIa blocker with oral activity.

Sibrafiban (RO 48-3657), an orally active, nonpeptide double-prodrug of Ro 44-3888, is a selective glycoprotein IIb IIIa receptor antagonist that inhibits platelet aggregation [1] [2] [3].

Tirofiban HCl is an antagonist of platelet glycoprotein-IIb/IIIa receptor.

Batifiban, a glycoprotein IIb/IIIa antagonist, is used potentially for the treatment of coronary artery disease.

Fradafiban binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM. Fradafiban is a non-polypeptide platelet glycoprotein IIb/IIIa antagonist.

AR-H067637 is a rapid-binding, reversible and potent (inhibition constant K(i) = 2-4 nM), competitive inhibitor of thrombin, as well as of thrombin bound to fibrin (clot-bound thrombin) or to thrombomodulin. The total amount of free thrombin generated in

Fradafiban (BIBU-52) hydrochloride is a nonpeptide antagonist of the platelet glycoprotein IIb IIIa complex, exhibiting a dissociation constant (Kd) of 148 nM for binding affinity to the human platelet GP IIb IIIa.

Orbofiban Acetate is a compound that serves as an antagonist to the platelet GPIIb/IIIa receptor, effectively inhibiting platelet aggregation when administered orally.

Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

DMP 728 is an antagonist of Glycoprotein IIb-IIIa.

Lamifiban is a nonpeptide glycoprotein IIb/IIIa antagonist. It prevents platelet loss during experimental cardiopulmonary bypass.

Variabilin, a novel inhibitor of human platelet aggregation, it is a potent RGD (Arg-Gly-Asp)-containing antagonist of the fibrinogen receptor glycoprotein IIb-IIIa (GPIIb-IIIa; αIIbβ3) and the vitronectin receptor αvβ3.Variabilin is also an antimicrobial furanosesterterpene. Variabilin is an inhibitor of human secretory and cytosolic phospholipase A2 (PLA2) activities that controls eicosanoid production in vitro and in vivo, inhibits neutrophil degranulation and superoxide generation in vitro and shows anti-inflammatory activity after topical or p.o. administration to mice.

Abciximab (C7E3) is a mouse human chimeric monoclonal antibody that is a potent glycoprotein IIb IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb IIIa, vitronectin and Mac-1 receptors.

SR121566A is a novel non-peptide antagonist of Glycoprotein IIb IIIa (GP IIb-IIIa).

TAK 029 is a local glycoprotein IIb/IIIa receptor inhibitor.

MK 0852 is the platelet GP IIb/IIIa cyclic heptapeptide antagonist.

SK&F 107260 is an RGD-containing peptide. It is a potent GP IIb/IIIa antagonist and a vitronectin antagonist.

Krds peptide is a synthetic tetrapeptide derived from lactotransferrin (residues 39 to 42) that suppresses binding of monoclonal antibody against glycoprotein IIb-IIIa on ADP-Stimulated platelets and megakaryocytes.

Lotrafiban is an orally active platelet membrane glycoprotein IIb/IIIa blocker that can be used in the treatment of coronary heart disease and cerebrovascular disease.

Potent irreversible αVβ3 integrin antagonist (Ki = 0.27 nM). Disrupts attachment of osteoclasts to bone and inhibits bone reabsorption (IC50 = 0.1 nM). Prevents ADP-induced platelet aggregation via inhibition of glycoprotein IIb/IIIa (GpIIb/IIIa, αIIbβ3)

Eptifibatide (Eptifibatide Acetate), an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class, is a cyclic heptapeptide constructed from 6 amino acids and a mercaptopropionyl residue.